BioSpace News Archive

C-RAD has signed a Letter of Intent with the Belgium company Ion Beam Applications SA, regarding the supply of C-RAD’s surface tracking solution.

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2020 cash capital offering of ordinary shares in Taiwan, with the record date of June 30, 2020.

The EndBrainCancer Initiative announced that GT Medical Technologies, manufacturers of GammaTile Therapy for Brain Cancer Patients, has joined EBCI’s roster of corporate partners.

Osmotica Pharmaceuticals plc through its subsidiary Osmotica Pharmaceutical US LLC, a fully integrated biopharmaceutical company, announced that the Company has resubmitted its New Drug Application for arbaclofen extended release tablets for the alleviation of spasticity in Multiple Sclerosis patients to the U.S. Food and Drug Administration.

- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set - - Achieved Statistical Significance on Primary Endpoint (p=0.020) in Pre-Planned Ad Hoc Analysis of Patients with Full Methylation of the FMR1 Gene Comprising 80% of the Study Population - - Zynerba to host conference call and webcast today, June 30, 2020 at 8:30 am ET - DEVON, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovat

MediWound Ltd. announced it has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking the approval of NexoBrid® for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Takeda has also led Carmine’s convertible note seed+ funding round by extending a $5M convertible loan to Carmine

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that the final data analysis from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis has been completed.

CoreLink, LLC , a leading designer and manufacturer of spinal implant systems, today announced the commercial launch and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the F3D-C2 Stand-alone Cervical System . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005144/en/ The F3D-C2 Stand-alone Cervical Spine System features an additiv

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, provides today an update on material business developments per Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements . The Company continues to rely on th